| Business Summary | | Mediscience
Technology
Corp.
is
principally
engaged
in
the
design
and
development
of
diagnostic
medical
devices
that
detect
cancer
using
light
induced
native
tissue
fluorescence
spectroscopy
to
distinguish
between
malignant
and
normal,
or
benign
tissue.
Animal
and
human
tissue
contains
molecules
that
fluoresce
naturally
when
exited
by
light
at
certain
wavelengths.
Since
the
molecular
and
or
structural
makeup
of
tissue
changes
as
it
becomes
cancerous,
the
Company's
medical
devices
are
able
to
detect
a
shift
in
the
resulting
native
tissue
fluorescence
spectrum
allowing
it
to
distinguish
between
normal,
precancerous
and
cancerous
tissue.
These
include
the
Cancer
Detection
(CD)
Scan,
CD
Ratiometer
and
CD
Map. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Mediscience
Technology
Corp.
designs
and
develops
proprietary
diagnostic
medical
devices
that
detect
cancer
using
light
induced
native
tissue
fluorescence
and
Raman
spectroscopy
to
distinguish
between
malignant
and
normal
tissue.
For
the
three
months
ended
5/31/01,
the
Company
reported
no
revenues.
Net
loss
fell
14%
to
$167
thousand.
Revenues
reflect
the
absence
of
a
marketable
product.
Lower
loss
reflects
lower
general
and
administrative
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2001 Pay | |
| Peter Katevatis, 67 Chairman,
Chief Exec. and Treasurer | $262K | Sidney Braginsky Pres,
COO | -- | John Kennedy, 64 VP,
Sec. | -- | Dollar amounts are as of 28-Feb-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|